UnknownPhase 1/2

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

40 participantsStarted 2023-10-01

Plain-language summary

Prostate specific membrane antigen (PSMA) is a type II transmembrane protein and acts as a glutamate carboxypeptidase enzyme. It is first described in prostate cancer cell lines and later identified in various tissues, include salivary gland. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093 in primary sjogren's syndrome patients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * pathological diagnosis confirmed by operation or biopsy. * Obtain written informed consent and accepted follow-up. Exclusion Criteria: * Pregnant, lactating women or having parenting plans during the study * Head and neck radiotherapy history ; * Active hepatitis C infection (PCR positive), include immunodeficiency syndrome, sarcoidosis, amyloidosis, graft versus host disease, IgG4 related diseases. * Other situaition researchers considered it was not appropriate to participate in trials.

What they're measuring

Diagnostic performance

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT06049368

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-30

Contact for this trial

Zhaohui Zhu, MD

86-13611093752 13611093752@163.com

View on ClinicalTrials.gov More Primary Sjögren Syndrome trials